Dyne Therapeutics, Inc. (DYN) insider trading

By person

29 insiders · 478 transactions

9.7×

John G. Cox holds 9.7 times base salary in stock. $7.00M of shares against $721.00K in salary for 2025.

Salary from the company's own proxy. The shares are what John G. Cox last reported holding, valued at $16.00, the price Common Stock was last bought or sold at on the open market here, on 2 Oct 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Jason P Rhodes

Director

$10.00M (1)

$173.35M (114) scheduled

−$163.35M

428,946

0.2297%

$6.86M

—

Dirk Kersten

Director

$30.00M (2)

$136.30M (88) scheduled

−$106.30M

3,586,796

1.92%

$57.39M

—

Atlas Venture Fund XI, L.P. entity

10% owner

—

$42.83M (29) scheduled

−$42.83M

6,562,578

3.51%

$105.00M

+321.5%

Joshua T Brumm

CEO & President

—

$26.68M (31) scheduled

−$26.68M

537,998

0.2881%

$8.61M

—

VV Manager II, LLC entity

10% owner

$15.49M (2)

—

+$15.49M

79,921

0.0428%

$1.28M

—

Logos Global Management LP entity

10% owner

$13.30M (1)

—

+$13.30M

1,504,392

0.8056%

$24.07M

—

Ra Capital Management, L.p. entity

10% owner

$12.54M (1)

—

+$12.54M

2,805,045

1.50%

$44.88M

—

Atlas Venture Opportunity Fund II, L.P. entity

10% owner

$10.00M (1)

—

+$10.00M

934,581

0.5005%

$14.95M

—

Richard William Scalzo

SVP, Head of Finance & Admin.

—

$8.71M (40) scheduled

−$8.71M

122,330

0.0655%

$1.96M

—

Susanna Gatti High

Chief Operating Officer

—

$7.06M (28) scheduled

−$7.06M

131,636

0.0705%

$2.11M

—

Jonathan McNeill

Chief Business Officer

—

$5.63M (34) scheduled

−$5.63M

132,106

0.0707%

$2.11M

+563.9%

Oxana Beskrovnaya

Chief Scientific Officer

—

$3.50M (30) scheduled

−$3.50M

195,840

0.1049%

$3.13M

—

Atlas Venture Opportunity Fund I, L.P. entity

10% owner

—

$1.40M (2) scheduled

−$1.40M

2,306,079

1.23%

$36.90M

−2.0%

John Cox

CEO & President

$1.97M (9)

$581.33K (9) scheduled

+$1.39M

437,507

0.2343%

$7.00M

+725.5%

Wildon Farwell

Chief Medical Officer

—

$955.49K (21) scheduled

−$955.49K

143,222

0.0767%

$2.29M

—

Carlo Incerti

Director

—

$474.05K (1) scheduled

−$474.05K

0.0000%

$0.00

—

Douglas Kerr

Head of R&D and CMO

—

$325.76K (11) scheduled

−$325.76K

170,564

0.0913%

$2.73M

—

Brian S Posner

Director

$314.84K (8)

—

+$314.84K

27,000

0.0145%

$432.00K

+217.6%

Erick Lucera

Chief Financial Officer

—

$228.68K (4) scheduled

−$228.68K

119,766

0.0641%

$1.92M

—

Johanna Friedl-Naderer

Chief Commercial Officer

—

$60.86K (11) scheduled

−$60.86K

152,897

0.0819%

$2.45M

—

Forbion Capital Fund IV Cooperatief U.A. entity

10% owner

—

6,131,079

3.28%

$98.10M

—

Wellington Biomedical Innovation Master Investors (Cayman) I L.P.

10% owner

—

1,608,785

0.8615%

$25.74M

—

CureDuchenne Ventures, LLC entity

10% owner

—

602,972

0.3229%

$9.65M

—

Romesh Subramanian

Chief Scientific Officer

—

566,249

0.3032%

$9.06M

+7.9%

Catherine Stehman-Breen

Director

—

115,713

0.0620%

$1.85M

+10.2%

Edward Hurwitz

Director

—

91,081

0.0488%

$1.46M

—

Mpm Bioventures 2018, L.p.

10% owner

—

91,081

0.0488%

$1.46M

—

Lawrence Otto Klein

Director

—

10,725

0.0057%

$171.60K

—

David Charles Lubner

Director

—

0.0000%

$0.00

—

Dyne Therapeutics, Inc.

What the insiders did Net buying

By person